Regeneron Pharmaceuticals, Inc.

Incyte Corporation

Bristol-myers Squibb Pharma Company

Amy Han

William C Olson

Andrew J Murphy

Brian Walter Metcalf

Chu-Biao Xue

Changsheng Zheng

Darius J Robinson

Thomas Nittoli

Jesper Gromada

Anlai Wang

Hao Feng

Ganfeng Cao

Frank Delfino

Christopher Daly

Viktoria Gusarova

Sokol Haxhinasto

Matthew Sleeman

Yingxin Zhang

Mimi Lifen Quan

Gavin Thurston

John Matthew Fevig

Christos Kyratsous

Peter W Glunz

Charles G Clark

James Russell Pruitt

Taisheng Huang

Haruka Okamoto

Marcus Kelly

Donald J Pinto

Lorin Andrew Thompson

Celia Dominguez

Patrick Y Lam

Renhua Li

Julian Andreev

Anna Zumsteg

Li Zhang

Christopher D'Souza

Andres Perez Bay

Taishing Huang

Andrew Murphy J

Described herein are protein steroid conjugates that are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to cells.

Steroids and protein-conjugates thereof

Provided herein are compounds, compositions and methods for the treatment of diseases and disorders associated with the liver X receptor, including bis-octahydrophenanthrene carboxamides and protein (e.g., antibody) drug conjugates thereof.

Bis-octahydrophenanthrene carboxamides and protein conjugates thereof

Described herein are protein-drug conjugates and compositions thereof that are useful, for example, for targeting glucagon-like peptide 1 receptor (GLP1R). In certain embodiments, provided are peptidomimetic payloads and linker-payloads and methods of making same. More specifically, GLP1 peptidomimetics, antibody-drug conjugates, and compositions which comprise anti-GLP1R antibodies and GLP1 peptidomimetic payloads and methods of treating GLP1R-associated conditions are provided.

Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof

Provided herein are compounds or payloads, linker-payloads, antibody-drug conjugates, and compositions, and methods for the treatment of diseases and disorders associated with the liver X receptor, including bis-octahydrophenanthrene carboxamides and protein (e.g., antibody) drug conjugates thereof.

Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists

Provided herein are compounds, compositions, and methods for the treatment of diseases and disorders associated with cancer, including tubulysins and protein (e.g., antibody) drug conjugates thereof.

Tubulysins and protein-tubulysin conjugates

Described herein protein drug conjugates and compositions thereof that are useful, for example, for the target-specific delivery of drugs to cells. By administering these compounds, compositions, and conjugates as described herein to specific target cells, side-effects due to non-specific binding phenomena, for example, to non-target cells are reduced. In certain embodiments, compounds, compositions, and conjugates are provided, which include hydrophilic residues in linker-payloads and protein conjugates thereof.

Hydrophilic linkers for antibody drug conjugates

Described herein protein steroid conjugates that are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to cells.

Steroids and antibody-conjugates thereof

Provided herein are bispecific antigen-binding molecules that bind HER2 and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human HER2. The bispecific antigen-binding molecules cluster on the surface of HER2 IHC2+ and IHC3+ cells, and are internalized into the cellular lysosomes. Also included are antibody-drug conjugates (ADCs) comprising the antibodies or bispecific antigen-binding molecules provided herein linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treating cancer in a subject by administering to the subject a bispecific antigen-binding molecule or an ADC thereof.

Bispecific antigen binding molecules that bind HER2, and methods of use thereof

Provided herein are monoclonal antibodies, and antigen-binding fragments thereof, that bind fibroblast growth factor receptor 2 (FGFR2), and methods of use thereof and methods of use thereof. Also included are antibody-drug conjugates (ADCs) comprising the anti-FGFR2 antibodies or antigen-binding fragments thereof linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treatment using the same.

Anti-FGFR2 antibodies and methods of use thereof

Provided herein are methods and compositions for site-specific conjugation of antibodies in the presence of a transglutaminase.

Optimized transglutaminase site-specific antibody conjugation

Provided herein are compounds, compositions, conjugates and methods for the treatment of diseases, and/or conditions such as, but not limited to, proliferative diseases. In certain embodiments, compounds, compositions, and conjugates are provided, which include cyclodextrin-based linker-payloads and protein conjugates thereof, and/or in combination with other agents. By administering these compounds, compositions, and conjugates as described herein to specific target cells, side-effects due to non-specific binding phenomena, for example, to non-target cells are reduced.

Cyclodextrin protein drug conjugates

Provided herein are antibodies and antigen-binding fragments that bind MSR1 and methods of use thereof. According to certain embodiments, the antibodies bind human MSR1 with high affinity. In certain embodiments, the antibodies bind MSR1 without blocking, or blocking less than 90%, of modified LDL binding to MSR1. In some embodiments, the antibodies bind cell surface expressed-MSR1 and are internalized. The antibodies of the invention may be fully human antibodies. The invention includes anti-MSR1 antibodies, or antigen-binding fragments thereof, conjugated to drugs or therapeutic compounds.

Anti-MSR1 antibodies and methods of use thereof

The present invention relates to 3-aminopyrrolidine derivatives of the formula I: (wherein R, R, R, R, R, R, R, R, X, Y and X are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as a modulator of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.

3-aminopyrrolidine derivatives as modulators of chemokine receptors

Growing community of inventors

Hockessin, DE, United States of America

Amy Han